(5)

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 38/08 — A1

(11) International Publication Number: **WO 99/43339**

(43) International Publication Date: 2 September 1999 (02.09.99)

(21) International Application Number: PCT/SE99/00262

(22) International Filing Date: 24 February 1999 (24.02.99)

(30) Priority Data:
9800550-7 24 February 1998 (24.02.98) SE

(71) Applicant *(for all designated States except US)*: A+ SCIENCE INVEST AB [SE/SE]; Kungsportsavenyn 31–35, S–400 10 Göteborg (SE).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: FÄNDRIKS, Lars [SE/SE]; Askims Ängsväg 14, S–436 40 Askim (SE). PETTERSSON, Anders [SE/SE]; PI 13066, S–442 97 Kode (SE). HALLBERG, Anders [SE/SE]; Björklundavägen 4A, S–756 46 Uppsala (SE).

(74) Agent: AWAPATENT AB; P.O. Box 11394, S–404 28 Göteborg (SE).

(81) Designated States: AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: A PHARMACEUTICAL PREPARATION COMPRISING AN ANGIOTENSIN II TYPE 2 RECEPTOR AGONIST, AND USE THEREOF

(57) Abstract

A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, which can be either a peptide or a peptide mimetic, said preparation being useful for treatment and prophylaxis of disorders of the alimentary tract, such as dyspepsia, irritable bowel syndrome and multiple organ failure. Use of an angiotensin II type 2 receptor agonist for the manufacture of a medicament for treatment and/or prophylaxis of disorder of the alimentary tract, such as dyspepsia, irritable bowel syndrome and multiple organ failure. A method for treatment and/or prevention of a condition selected from the group consisting of disorders of the alimentary tract, such as dyspepsia, irritable bowel syndrome and multiple organ failure in a patient, wherein an effective amount of an angiotensin II type 2 receptor agonist is administered to the patient.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

A PHARMACEUTICAL PREPARATION COMPRISING AN ANGIOTENSIN II TYPE 2 RECEPTOR AGONIST, AND USE THEREOF

Technical field of the invention

The present invention relates to a pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, as well as to a method for prophylaxis and treatment of disorders of the alimentary tract, such as dyspepsia, irritable bowel syndrome and multiple organ failure.

Background art

Functional disorders of the gastrointestinal tract are very common and are characterised by the absence of signs of organic disease, such as peptic ulcers or ulcerative colitis. The symptomatology may be due to an organic disease, such as peptic ulcer disease, or, more commonly, may be without any known origin, i.e. absence of organic pathology in the gut as evidenced by various diagnostic procedures. In clinical routine the symptom-syndrome is commonly divided into two groups: "dyspepsia" ("non-ulcer dyspepsia", "functional dyspepsia", "non organic dyspepsia") or "irritable bowel syndrome", depending on whether the symptoms appear to be elicited from the upper or lower part of the gut, respectively. Furthermore, on the individual basis, there may be a considerable overlap between these two groups of symptoms.

Dyspepsia and irritable bowel syndrome are two of the most frequent health conditions encountered in the general population. Epidemiological studies have reported prevalence rates of 25-30% annually if restricted to those who have recurrent abdominal symptoms.

The exact mechanisms behind functionally related complaints from the gastrointestinal tract are today unknown. It is believed that they depend on dyscoordination of the functional state in various segments along the gut

axis and/or an increased sensitivity of the sensory systems mediating the perceptions. It has become evident in the art that subjective symptoms are integrated responses to changes in gut subfunctions; i.e. the balance between the digestive processes per se and mucosaprotective barrier functions (protective secretions, motility and immunological host defence systems).

One well-known group of dyspeptic symptoms is "acid-related". The definition of acid-related dyspepsia is that there occurs a symptom-relief when stomach acidity is lowered by use of antacids or antisecretagogues. A prerequisite for acid-related dyspeptic symptoms is that luminal acid gets access to the superficial mucosal cells where the sensory receptors are located. This is not the case during normal conditions, as a continuos transport of fluid and bicarbonate provides a neutral compartment at the mucosal surface. This important acid neutralisation on the mucosal surface is dependent on alkaline volume secretion and mixing transport of the luminal contents by co-ordinated intestinal wall movements. If the surface neutralisation process is down-regulated, e.g. by certain stress conditions or drugs (e.g. non-steriodal antiinflammatory drugs), mucosal acidification may occur allowing for perception of abdominal discomfort either due to direct activation of mucosal acid-receptors, or indirectly by changed wall motility registered by nociceptors in the muscle layers of the gut.

Dyspepsia due to peptic ulcers can be cured by intake or antacids and inhibitors of gastric acid secretion. Ulcer-like dyspeptic symptoms without known organic cause are usually sensitive to similar treatment. As mentioned, acid related dyspepsia is defined by the symptom-relief in association with the intake of neutralising agents or inhibition of gastric acid production by use of proton pump inhibitors or histamine type 2 receptor antagonists. However, the former principle is shortlasting and neutralising drugs must thus be administered repeat-

edly during the day. The latter drugs have disadvantages of being expensive and exert a great impact on the gut physiology as the anacid gastric conditions increase the risk for intestinal and/or systemic infections. Prokinetic drugs, such as cisapride, modulating gut wall motility; anticholineric compounds inhibiting acid secretion and wall contractions; as well as prostglandine-analogues for preservation of mucosal integrity; are other principles that are utilised for dyspeptic symptoms and IBS, usually with low efficacy and high frequency of side effects. It follows that therapeutic regimens for treatment of functional disorders of the gut are largely lacking and those available are impaired by serious disadvantages.

Another condition in which the intestinal mucosaprotective functions are disturbed is multiple organ failure, MOF. Severe physical stress on the organism (life-threatening critical illness due to e.g. burn injuries or mechanical multitrauma) elicits a vasoregulatory response associated with down-regulation of the functional state of non-vital organs, preferentially the mesenteric organs. Distorted mucosa-protective functions are associated with acid-dependent gastric erosions and bleedings ("haemorrhaged stress-gastritis") and enables gut pathogens to cross the intestinal mucous and penetrate the mucosal epithelium to eventually spread to systemic compartments via lymphatic and blood vessels. The latter may have severe consequences as the microbial translocation elicits a systemic inflammatory response which, together with the initially compromised systemic circulation, leads to functional failure of various distant organs, e.g. kidney, heart, lungs, and haemostasis. Such a sequential development of devastating sequels is defined as multiple organ failure (MOF).

The treatment of multiple organ failure is very costly and results in long term treatments at intensive care units. Therapeutic efforts in MOF treatment today

are mainly aimed at lifesustaining treatments, such as administration of antibiotics, volume expansion and respiratory assistance. As a key-event in the development of MOF is a mucosal barrier dysfunction and it follows that therapeutic strategies that support mucosaprotective functions of the gut may improve or prevent the condition.

The renin-angiotensin system is a regulatory axis, which primarily is involved in circulation homeostasis but has also large impact on gut functions. One important factor in the renin-angiotensin system is angiotensin II. Angiotensin II is a polypeptide, more specifically an octapeptide, occurring in the sera of mammals, including humans. It is a hormone released when the mammal is subjected to stress, and it has a vasoconstrictive and thus blood pressure-raising effect. It also stimulates the secretion of aldosterone from the adrenal glands, which contributes to the blood pressure-raising effect. It is produced in the renin-angiotensin-aldosterone system by conversion of angiotensin I under the influence of the angiotensin-converting enzyme, ACE.

Although the existence of angiotensin II receptor subtypes has been suspected for some time, definite evidence for angiotensin II receptor heterogeneity has been obtained only with the recently introduced non-peptide angiotensin II receptor antagonists, exemplified with the prototypic compounds DuP 753 (losartan) and PD 123177. The sites having high affinity for DuP 753 are designated as site 1 - angiotensin II type 1 receptors - and those having high affinity for PD 123177 as site 2 - angiotensin II type 2 receptors. The function of angiotensin II type 2 receptors has been unidentified in spite of numerous investigations.

Activation of angiotensin II-type 2 receptors are involved in the reduction of mesenteric blood flow and the decreased mucosaprotective functional state during various stress conditions. Thus, one possible way to pre-

vent dyspeptic symptoms and MOF is to block the formation of angiotensin II. This may be done by administration of angiotensin converting enzyme inhibitors (ACE-inhibitors), i.e. compounds that block the formation of angiotensin II. This method has for example been shown to improve mesenteric oxygenation during severe shock.

The use of ACE-inhibitors for treatment of gut disorders is, however, hampered by the fact that they are acting as non-specific enzyme inhibitors, resulting in accumulation of several vasoactive peptides, e.g. bradykinin, substance P, and endogenous opoids. This may lead to instable blood pressure regulation as well as an increased risk for allergic manifestations and upper airway irritation. Another way to prevent MOF is to block the angiotensin II type 1 receptors. This is known from the patent application PCT/SE96/00602 (claiming priority from the Swedish patent application No. 9501881-8), wherein the use of angiotensin II type 1 receptor antagonists for treatment and prophylaxis of MOF is described. The effect of these agonists is a pharmacological specific blockade of angiotensin II type 1 receptors resulting in an increase of gastrointestinal tissue oxygenation in turn reinforcing the mucosal barrier function in the upper gastrointestinal tract.

Summary of the invention

The object of the invention is to provide a pharmaceutical preparation as well as a method for treatment of condition affecting the alimentary tract, such as dyspepsia, irritable bowel syndrome or multiple organ failure.

The invention is based on a new, until now unknown functional role for a subclass of angiotensin II receptors. Selective stimulation of angiotensin II type 2 receptors has been found to elicit a profound activation of gastroduodenal mucosal alkaline secretion and gut motility, effects which lead to a strengthening of the intestinal mucous membrane, thus counteracting conditions of

the alimentary tract, such as dyspepsia, irritable bowel syndrome or by multiple organ failure.

Thus, the present invention relates to a pharmaceutical preparation comprising at least one angiotensin II type 2 receptor agonist or a physiologically acceptable salt thereof.

The invention also relates to use of an angiotensin II type 2 receptor agonist or a physiologically acceptable salt thereof for the manufacture of a medicament for treatment and/or prophylaxis of a disorder of the alimentary tract, such as dyspepsia, or of multiple organ failure.

Furthermore, the invention relates to a method for treatment and/or prevention of an affection selected from the group consisting of disorders of the alimentary tract, such as dyspepsia, irritable bowel syndrome and/or multiple organ failure in a patient, characterised in that an effective amount of at least one angiotensin II type 2 receptor agonist or a pharmaceutically acceptable salt thereof is administered to the patient.

The characterising features or the invention will be evident from the following description and the appended claims.

Detailed description of the invention

The term "angiotensin II type 2 receptor agonist" used herein relates to any compound binding specifically to, and thus stimulating, angiotensin II type 2 receptors.

The term "patient" used herein relates to all kinds of mammals, including humans, in need of treatment and/or prophylaxis according to the invention.

Thus, according to the present invention an angiotensin II type 2 receptor agonist or a pharmaceutically acceptable salt thereof. The agonist used according to the invention may be any substance, derived from natural sources or from synthesis by chemical and/or genetic en-

gineering methods, functioning as an angiotensin II type 2 receptor agonist. The agonist may be either a peptide or a peptide mimetic with high selectivity for the angiotensin II type 2 receptor.

Examples of peptides functioning as angiotensin II type 2 receptor agonist and thus suitable for use according to the present invention are p-aminophenylalanine^6-angiotensin II or N-α-nicotinoyl-Tyr-(N-α-CBZ-Arg)-Lys-His-Pro-Ile-OH.

When p-aminophenylalanine^6-angiotensin II is used, it is preferably administered to the patient directly into the blood. This peptid has a short length of life and will therefore only have an effect for a limited time. This enables an easy control of the effects.

However, since many peptides, including p-aminophenylalanine^6-angiotensin II, are difficult to use directly as drugs due to problems such as poor solubility, poor gastrointestinal absorption and short biological half-times, it may be advantageously to use a peptide mimetic. A peptide mimetic may contain elements that enforce steric constraints of a peptide and a peptide mimetic may retain some peptidic character. A peptide mimetic may alternatively be lacking peptidic fragments and consist of an organic molecule. A peptide mimetic can be an organic molecule comprising biaryl, arylheteroaryl, or biheteroaryl fragments that can be attached to a nitrogen containing monocyclic or bicyclic heterocycle by a one, two or three atom linker. A selective angiotensin II type 2 receptor agonist may be an analogue of the non-selective angiotensin II type 2 receptor ligand 5,7-dimethyl-2-ethyl-3-[[4-[2(n-butyloxycarbonylsulfonamido)-5-isobutyl-3-thienyl]phenyl]methyl]-imidazo[4,5-b]-pyridine

It is preferable to use a selective angiotensin II type 2 agonist. However, it is also possible to use non-selective angiotensin II type 2 agonists. In order to block the negative effects that these non-selective ago-

nists may cause due to their influence on the angiotensin II type 1 receptor, it is suitable to combine them with a angiotensin II type 1 receptor antagonist in order to block the angiotensin II type 1 receptor. Several angiotensin II type 1 receptor antagonists are known in the art; examples of suitable substances are e.g. described in the patent application PCT/SE96/00602 (claiming priority from the Swedish patent application No. 9501881-8).

The pharmaceutical preparations according to the invention may be any kind of conventionally used preparations. Besides the angiotensin II type 2 receptor agonist, the pharmaceutical preparations according to the invention may comprise other substances such as e.g. physiologically acceptable additives, such as a solvent, an adjuvant, a carrier and/or a suitable preservative. Preferably, the pharmaceutical preparations according to the invention have the form of solutions for injection, but they may also be e.g. solutions, suspensions, tablets or capsules intended for oral, sublingual or rectal administration.

The pharmaceutical preparations according to the invention are particularly useful for prophylaxis and/or treatment of multiple organ failure, dyspepsia and other disorders affecting the alimentary tract.

According to the present invention it is thus possible to treat and/or prevent disorders of the alimentary tract or gastrointestinal disorders. Examples of such disorders include xerostomia, gastro-oesophageal reflux disease, oesophagitis, gastritis, gastroparesis, gastroduodenal ulcer disease, non ulcer dyspepsia, hyperacidity, pancreatitis, disorders of the biliary tract, coeliacia, Crohn's disease, ulcerative colitis, diarrhoea, constipation, irritable bowel disease, colic, dysphagia, obesitas, vomiting, nausea, indigestion and Sjögren's syndrome.

The invention will be further explained in the following examples. These examples are only intended to il-

lustrate the invention and should in no way be considered to limit the scope of the invention.

Example 1

In this in-vivo example, the angiotensin II type 2 receptor agonist p-aminophenylalanine^{6}-angiotensin II, a peptide obtained from SIGMA (Product No. A1811), was used. This agonist was administered intravenously to a chloralose-anesthetized rat prepared for in-situ titration of duodenal mucosal alkaline secretion (the methodological is described by Flemström et al in Am. J. Physiol. 1982, 243: G348). It was found that increasing infusion rates of the compound stimulated markedly the mucosal alkalinisation in a dose-dependent fashion, which is illustrated in the table below.

In order to further illustrate the receptor specificity of the agonist, it was also administered in the presence of an specific angiotensin II type 2 reeeptor antagonist (PD123319, 200 µg/kg intravenously), without any obvious side effects on global parameters such as mean arterial pressure. The mucosal alkalinisation was then counteracted. This is also illustrated in table 1 below, in the right column.

The values given in the table represent group-means (± standard error) of the secretory level obtained after 30 min infusion.

Table 1

Dose of agonist µg/(kg·h)	Mucosal alkaline secretion µEq/(cm intestine · h)	
	Rat treated with the agonist (n=5)	Rat treated with the agonist in presence of an antagonist (n=5)
0	12 ± 1	11 ± 1,5
0,75	11 ± 1	12 ± 2
2,5	19 ± 3	12 ± 2
7,5	25 ± 4	14 ± 2,5
25	25 ± 3	18 ± 4

Example 2

In this in-vivo example, the selective angiotensin II type 2 receptor agonist CGP 42112A (N-α-nicotinyl-Tyr-(N-α-CZB-Arg)Lys-His-Pro-Ile-OH), a peptide obtained from NEOSYSTEM S.A., France (product number SC431, was used. This agonist was administered intravenously to chloralose-anaesthetised rats prepared for in-situ titration as described in Example 1.

It was found that a single dose of CGP 42112A (0.1 µg/kg x min) increased the duodenal mucosal bicarbonate secretion as shown in table 2 below. Co-administration of the specific angiotensin II type 1 receptor antagonist losartan (10 mg/kg intravenously) did not affect the stimulatory response, as shown in the table below.

In order to further illustrate the receptor specificity of the agonist, CGP 42112A was also administered together with a specific angiotensin II type 2 receptor antagonist PD123319 (200 µg/kg intravenously). The duodenal mucosal alkaline secretion was then effectively blocked. This is also shown in table 2.

Table 2

Dose of agonist (µg/kg x min)	Increase in duodenal mucosal alkaline secretion (% increase compared to baseline)		
	Rats treated with agonist alone	Rats pre-treated with losartan	Rats pre-treated with PD123319
0.1	58	55	3

Example 3

In this in-vivo example, the endogenous ligand of angiotensin II receptors, Angiotensin II, obtained from SIGMA, was used. This agonist was administered intravenously to chloralose-anaesthetised rats prepared for in-situ titration as described in Example 1.

It was found that angiotensin II given alone did not increase the duodenal mucosal alkaline secretion, as shown in table 3 below.

After pre-treatment with the specific angiotensin II type 1 receptor antagonist losartan (10 mg/kg intravenously), angiotensin II infusion stimulated duodenal mucosal alkaline secretion, as evident from the table.

Co-administration of the specific angiotensin II type 2 receptor antagonist PD 123319 (200 µg/kg intravenously) effectively counteracted the stimulatory response, also evident from the table.

Table 3

Dose of agonist (µg/kg x h)	Increase in duodenal mucosal alkaline secretion (% increase compared to baseline)		
	Rats treated with agonist alone	Rats pre-treated with losartan	Rats pre-treated with PD123319
0.25	0	23	6
0.75	0	92	8

Example 4

In this in-vivo example, the non-selective angiotensin II receptor agonist L-162,312, a non-peptidergic compound, was used. This agonist was administered intravenously to chloralose-anaesthetised rats (n=6) prepared for in-situ titration as described in Example 1.

After pre-treatment with the specific angiotensin II type 1 receptor antagonist losartan (10 mg/kg intravenously), L-162,313 infusion (0.3 mg/kg bolus injection i.v., followed by continuos infusion of 0.03 mg/kg x h) increased duodenal mucosal alkaline secretion by 86% compared to baseline.

Co-administration of the specific angiotensin II type 2 receptor antagonist PD 123319 (200 µg/kg intravenously) effectively counteracted the stimulatory response of L-162,313 in losartan pre-treated animals.

CLAIMS

1. A pharmaceutical preparation comprising at least one angiotensin II type 2 receptor agonist or a physiologically acceptable salt thereof.

2. A pharmaceutical preparation according to claim 1, wherein the agonist is a substance derived from natural sources.

3. A pharmaceutical preparation according to claim 1, wherein the agonist is a synthetic substance.

4. A pharmaceutical preparation according to any one of claims 1 - 3, wherein the agonist is a selective angiotensin II type 2 receptor agonist.

5. A pharmaceutical preparation according to any one of claims 1 - 3, wherein the agonist is a non-selective angiotensin II type 2 agonist, and said pharmaceutical preparation further comprises at least one angiotensin II type 1 receptor antagonist.

6. A pharmaceutical preparation according to any one of claims 1 - 5, wherein the agonist is a peptide.

7. A pharmaceutical preparation according to claim 6, wherein the peptide is p-aminophenylalanine^{6}-angiotensin II or N-α-nicotinoyl-Tyr-(N-α-CBZ-Arg)-Lys-His-Pro-Ile-OH.

8. A pharmaceutical preparation according to any one of claims 1 - 5, wherein the agonist is a peptide mimetic.

9. A pharmaceutical preparation according to claim 8, wherein the peptide mimetic is an organic molecule structurally related to non-selective angiotensin II type 2 receptor ligands, such as 5,7-dimethyl-2-ethyl-3-[[4-[2(n-butyloxycarbonylsulfonamido)-5-isobutyl-3-thienyl]-phenyl]methyl]-imidazo[4,5-b]pyridine.

10. A pharmaceutical preparation according to any one of claims 1 - 9, for prophylaxis and/or treatment of a disorder of the alimentary tract.

11. A pharmaceutical preparation according to any one of claims 1 - 9, for prophylaxis and/or treatment of dyspepsia and irritable bowel syndrome.

12. A pharmaceutical preparation according to any one of claims 1 - 9, for prophylaxis and/or treatment of multiple organ failure.

13. Use of an angiotensin II type 2 receptor agonist or a physiologically acceptable salt thereof for the manufacture of a medicament for treatment and/or prophylaxis of a disorder of the alimentary tract, such as dyspepsia, irritable bowel syndrome or of multiple organ failure.

14. Use according to claim 13, wherein the agonist is a substance derived from natural sources.

15. Use according to claim 13, wherein the agonist is a synthetic substance.

16. Use according to any one of claims 13 - 15, wherein the agonist is a selective angiotensin II type 2 receptor agonist.

17. Use according to any one of claims 13 - 15, wherein the agonist is a non-selective angiotensin II type 2 agonist, and said medicament further comprises at least one angiotensin II type 1 receptor antagonist.

18. Use according to any one of claims 13 - 17, wherein the agonist is a peptide.

19. Use according to claim 18, wherein the peptide is p-aminophenylalanine6-angiotensin II or N-α-nicotinoyl-Tyr-(N-α-CBZ-Arg)-Lys-His-Pro-Ile-OH.

20. Use according to any one of claims 13 - 17, wherein the agonist is a peptide mimetic.

21. Use according to claim 20, wherein the peptide mimetic is an organic molecule structurally related to non-selective angiotensin II type 2 receptor ligands, such as 5,7-dimethyl-2-ethyl-3-[[4-[2(n-butyloxycarbonyl-sulfonamido)-5-isobutyl-3-thienyl]phenyl]methyl]-imidazo-[4,5-b]pyridine.

22. A method for treatment and/or prevention of a affection selected from the group consisting of disorders of the alimentary tract, such as dyspepsia, irritable bowel syndrome and/or multiple organ failure in a patient, characterised in that an effective amount of at least one angiotensin II type 2 receptor agonist or a pharmaceutically acceptable salt thereof is administered to the patient.

23. A method according to claim 22, wherein the agonist is a substance derived from natural sources.

24. A method according to claim 22, wherein the agonist is a synthetic substance.

25. A method according to any one of claims 22 - 24, wherein the agonist is a selective angiotensin II type 2 receptor agonist.

26. A method according to any one of claims 22 - 24, wherein the agonist is a non-selective angiotensin II type 2 agonist, which is administered in combination with at least one angiotensin II type 1 receptor antagonist.

27. A method according to any one of claims 22 - 26, wherein the wherein the agonist is a peptide.

28. A method according to claim 27, wherein the peptide is p-aminophenylalanine6-angiotensin II or N-α-nicotinoyl-Tyr-(N-α-CBZ-Arg)-Lys-His-Pro-Ile-OH.

29. A method according to any one of claims 22 - 26, wherein the agonist is a peptide mimetic.

30. A method according to claim 29, wherein the peptide mimetic is an organic molecule structurally related to non-selective angiotensin II type 2 receptor ligands, such as 5,7-dimethyl-2-ethyl-3-[[4-[2(n-butyloxycarbonyl-sulfonamido)-5-isobutyl-3-thienyl]phenyl]methyl]-imidazo-[4,5-b]pyridine.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 99/00262

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61K 38/08
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, MEDLINE, BIOSIS, EMBASE, DBA, CA, REGISTRY

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9639164 A1 (THE UNIVERSITY OF SOUTHERN CALIFORNIA), 12 December 1996 (12.12.96), claims 8 and 10; page 3, lines 24-27; page 11, lines 7-11	1-4,6-7, 10-12,22-25, 27-29
X	US 5444067 A (SALAH KIVLIGHN ET AL), 22 August 1995 (22.08.95), see claim 2	1-4,8-12, 22-25,29-30
X	WO 9614060 A1 (MARKLUND, STEFAN, L.), 17 May 1996 (17.05.96), claims 2, 21; and page 16, line 5	1-30
A	WO 9636336 A1 (ASTRA AKTIEBOLAG), 21 November 1996 (21.11.96)	1-30

[X] Further documents are listed in the continuation of Box C. [X] See patent family annex.

* Special categories of cited documents:
"A" document defining the general state of the art which is not considered to be of particular relevance
"E" erlier document but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
17 May 1999	20 -06- 1999
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86	Authorized officer Carolina Palmcrantz Telephone No. +46 8 782 25 00

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 99/00262

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9700070 A1 (ASTRA AKTIEBOLAG), 3 January 1997 (03.01.97) --	1-30

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 99/00262

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.: 22-30
because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claims 22-30 are directed to a method of treatment of the human/animal body the search has been carried out, based on the alleged effects of the compound/composition (c.f. PCT Rule 39.1(iv)).

2. [ ] Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

03/05/99

International application No.
PCT/SE 99/00262

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9639164 A1	12/12/96	AU 5990796 A	24/12/96
		CA 2221730 A	12/12/96
		EP 0828505 A	18/03/98
		US 5834432 A	10/11/98
US 5444067 A	22/08/95	GB 2281298 A	01/03/95
		GB 9416916 D	00/00/00
WO 9614060 A1	17/05/96	AU 3708295 A	31/05/96
WO 9636336 A1	21/11/96	AU 5784596 A	29/11/96
		BR 9608407 A	29/12/98
		CA 2219395 A	21/11/96
		CN 1184424 A	10/06/98
		CZ 9703454 A	18/03/98
		EP 0830131 A	25/03/98
		IL 118299 D	00/00/00
		NO 975221 A	13/11/97
		SE 9501881 D	00/00/00
		SK 151397 A	05/08/98
		ZA 9603569 A	19/11/96
WO 9700070 A1	03/01/97	AU 1184097 A	15/01/97
		BR 9608472 A	29/12/98
		CA 2225175 A	03/01/97
		CN 1192681 A	09/09/98
		CZ 9703730 A	13/05/98
		EP 0840607 A	13/05/98
		IL 122659 D	00/00/00
		NO 975922 A	16/12/97
		SE 9502219 D	00/00/00
		SK 172197 A	08/07/98